mPATH Health Secures Significant Funding for Cancer Initiatives
mPATH Health, a pioneering digital health company committed to enhancing cancer screening and preventive health, is excited to announce the successful closure of $3 million in funding. This crucial investment is set to bolster their mission of improving health outcomes for diverse populations. The funding package includes a $2 million Small Business Technology Grant from the National Cancer Institute (NCI) and a $1 million equity investment led by Oncology Ventures, a firm dedicated to transforming cancer care.
Impact of NCI Grant on Cancer Screening
The NCI grant, awarded early on, will significantly contribute to the commercialization of mPATH's innovative cancer screening program. This program has shown impressive results, effectively doubling screening rates among varied demographics, irrespective of race, ethnicity, or income levels. The financial boost will support further development and rigorous clinical evaluations of this groundbreaking program.
mPATH’s Commitment to Equal Health Access
Dr. David Miller, co-founder of mPATH, expressed pride in receiving this recognition and funding, stating, "This $3 million investment will enable us to broaden our reach, increase cancer screenings, and ultimately save lives. Additionally, it will enhance our program, allowing us to showcase its return on investment for health portfolios."
Growth Potential with Oncology Ventures
The partnership with Oncology Ventures represents a strategic move for mPATH, empowering them to rapidly advance their outreach initiatives and develop new screening modules. Ben Freeberg, Founder of Oncology Ventures, remarked, "We are enthusiastic about supporting mPATH as they provide critical preventive care services to underserved populations. This innovation will empower patients by ensuring timely access to relevant screenings."
Reducing Barriers to Cancer Treatment
Emphasizing the urgency of early intervention, Freeberg noted that every month of delayed cancer treatment can increase mortality rates by 10%. By improving access to vital screenings, mPATH is poised to play a significant role in enhancing cancer care outcomes on a larger scale.
Dedication to Health Equity and Innovation
mPATH is strongly focused on promoting health equity, aiming to improve cancer screening outcomes regardless of a patient's background. This funding milestone represents a pivotal moment in their journey, reflecting their commitment to redefining cancer prevention strategies and saving lives.
The Unique Approach of mPATH Health
By merging advanced technology with behavioral science, mPATH Health is transforming the landscape of preventive cancer screening. The company harnesses innovative techniques to empower individuals, encouraging them to take proactive steps toward their health by participating in regular screenings for early cancer detection.
About mPATH Health
mPATH Health specializes in revolutionizing preventive cancer screening through automation and personalized outreach. Their approach is designed to motivate individuals to prioritize their health, ensuring they are informed and prepared for regular cancer screenings. For more about their initiatives, visit their official webpage.
Frequently Asked Questions
What is mPATH Health's mission?
mPATH Health is dedicated to enhancing cancer screening access and improving health outcomes across diverse populations.
What is the amount of funding mPATH Health secured?
mPATH Health has successfully raised $3 million in funding through a combination of grants and investments.
How does NCI's grant benefit mPATH Health?
The NCI grant supports the advancement and clinical testing of mPATH's innovative cancer screening program, promoting wider accessibility.
Who are the major investors involved?
The major investors include the National Cancer Institute and Oncology Ventures, which aim to support transformative healthcare solutions.
What approach does mPATH Health take toward patient care?
mPATH Health integrates automations and behavioral science to foster preventive care, encouraging individuals to engage in early screenings.
